Adoptive Immunotherapy for Small Cell Lung Cancer by Expanded Activated Autologous Lymphocytes: a Retrospective Clinical Analysis

Zhang, Guo-Qing; Li, Fang; Sun, Sheng-Jie; Hu, Yi; Wang, Gang; Wang, Yu; Cui, Xiao-Xia; Jiao, Shun-Chang

추천

검색

자료유형: 학술저널

저자정보: Zhang, Guo-Qing (First Department of Medical Oncology, Chinese PLA General Hospital) Li, Fang (First Department of Medical Oncology, Chinese PLA General Hospital) Sun, Sheng-Jie (First Department of Medical Oncology, Chinese PLA General Hospital) Hu, Yi (First Department of Medical Oncology, Chinese PLA General Hospital) Wang, Gang (Laboratory of Tumor Research Center, Chinese PLA General Hospital) Wang, Yu (Beijing Immunotech Applied Science Limited) Cui, Xiao-Xia (Beijing Immunotech Applied Science Limited) Jiao, Shun-Chang (First Department of Medical Oncology, Chinese PLA General Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제4호

발행연도: 2015.1

수록면: 1,487 - 1,494 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: To investigate the clinical efficacy of expanded activated autologous lymphocytes (EAAL) in patients with small cell lung cancer (SCLC). Materials and Methods: A total of 32 SCLC patients were selected and randomly divided into EAAL treatment and control groups, 16 cases in each. EAAL were obtained by proliferation of peripheral blood mononuclear cells (PBMCs) of patients followed by phenotype determination. Clinical data of all patients were recorded. Patients of both groups were followed up and the overall survival (OS) were compared retrospectively. Results: After culture and proliferation in vitro, the percentages of $CD3^+$, $CD3^+CD8^+$, $CD45RO^+$, $CD28^+$, $CD29^+$, $CD8^+CD28^+$ and $CD3^+CD16^+/CD56^+$ cells increased markedly (p<0.05). The OS of the EAAL treatment group was longer than that of control group, but the difference was not statistically significant (p=0.060, HR=0.487, 95%CI 0.228~1.037). 1- to 3-year survival rates in EAAL treatment group were longer than those in control group, but there was still no significant difference (p>0.05). COX multivariate regression analysis showed that the number of chemotherapy cycles and the application of EAAL immunotherapy were independent prognostic factors for SCLC patients. The OS in females and chemotherapy${\leq}6$ cycles were obviously prolonged after EAAL immunotherapy. Conclusions: In vitro induction and proliferation of EAAL is easy and biologically safe. Generally, EAAL adoptive immunotherapy can evidently prolong the OS of SCLC patients.

#Adoptive immunotherapy #small cell lung cancer #expanded activated autologous lymphocytes

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!